Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Arcturus Therapeutics Holdings Inc. reported fiscal fourth quarter 2023 results: revenue $25.0, net income $11.7 million, EPS $0.44 per share.
- Period
- fiscal fourth quarter 2023
- Revenue
- $25.0
- Net income
- $11.7 million
- EPS
- $0.44 per share
- Result
- reported results
Exact text from the filing
the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Arcturus Therapeutics Holdings Inc. reported fiscal year ended December 31, 2023 results: revenue $157.7 million, net income $29.7 million, EPS $1.12 per share.
- Period
- fiscal year ended December 31, 2023
- Revenue
- $157.7 million
- Net income
- $29.7 million
- EPS
- $1.12 per share
- Result
- reported results
Exact text from the filing
the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.
View on SEC.gov